Pablo Cironi

Dedicated to increasing healthspan by restoring and preserving the function of the thymus.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.

aptaTargets is a clinical stage biopharmaceutical company focused in developing therapeutic applications based on aptamer technology. Our candidates are neuroprotectants and immunomodulators being developed from preclinical stages up to clinical proof-of-concept.

GlyCardial Diagnostics is a spin-off company of the Catalan Institute of Cardiovascular Sciences (ICCC) and the Spanish National Research Council (CSIC) focused on the development of a novel in vitro diagnostic device for myocardial ischemia. The technology is based on the detection of Apo J-Glyc in blood as a biomarker for the early diagnosis of cardiac ischemia and the prediction of patient’s evolution after an ischemic event. GlyCardial Diagnostics was created by scientists Lina Badimon, Judit Cubedo, Teresa Padró and Gemma Vilahur. The company is located at the Hospital de la Santa Creu i Sant Pau Art Nouveau Site in Barcelona. In 2014, it was recognised as one of the most original, impactful technology projects in Spain in the MIT Technology Review awards for innovators under 35.

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

ProteoDesign is a spin-out from Princeton University founded around a novel protein engineering platform technology.

SpliceBio is a biotechnology company exploiting Protein Splicing to develop the next generation of gene therapies. Our proprietary platform is based on technology developed in the Muir Lab at Princeton University after more than 20 years of pioneering intein and protein engineering research by our co-founders. The company is backed by UCB Ventures, Ysios Capital, NEA, Gilde Healthcare, Novartis Venture Fund and Asabys Partners.

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

MedLumics is a medical device company with the goal of taking the latest technological and scientific developments in biophotonics and turning them into innovative and quality products to improve the quality of life. Our work is focused on one of the most successful light-based diagnostic techniques, Optical Coherence Tomography, which is currently seeing rapid expansion and growth. Our disruptive technological advantages allow us to offer unique medical solutions and to develop the clinical applications of this imaging modality. MedLumics, Enlightening Healthcare

Dedicated to increasing healthspan by restoring and preserving the function of the thymus.

Criteria Bio Ventures is a leading life sciences venture fund looking to partner with transformative companies to shape the future of healthcare. We team up with driven entrepreneurs and fellow investors who aim to revolutionize healthcare through disruptive and well-protected innovations that have the potential to transform patients’ lives where there is a significant unmet medical need. We invest in private biotech companies in Europe and North America, with special focus in Spain and Portugal. We invest agnostically across therapeutic modalities and disease areas, offering evergreen support until achieving meaningful impact. Criteria Bio Ventures is part of Caixa Capital Risc and the CriteriaCaixa group, Spanish largest investment holding with €25+ Bn assets under management.

Founded by a team with a long cutting-edge translational expertise in regulatory T cells and mechanisms of tolerance, AbolerIS Pharma is developing novel and unique therapeutic approaches to finely regulate the immune system by inducing immune tolerance and preserving useful immune responses in inflammatory, autoimmune, and degenerative diseases.